Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“A representative from Gillibrand’s office said the five-year delay is meant to give the FDA time for rulemaking.”
VerifiedConfidence: HIGH

Reasoning

Both excerpts from the ProPublica article on the Clear Labels Act state that a representative from Senator Gillibrand’s office explained the five‑year delay is intended to give the FDA time for rulemaking. This directly confirms the claim.

On confidence: The claim is directly quoted in two independent excerpts from the same ProPublica article, which is a Tier 1 primary source.

Important context

The statement is part of a discussion about the Clear Labels Act and its legislative timeline, indicating the delay is linked to regulatory preparation.

Evidence

Supporting (2)

Limitations

The evidence comes from a single news outlet; while ProPublica is a reputable source, no additional independent confirmation is provided within the supplied documents.

Last verified:
Sep 27, 2026, 4:24 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

“A Clear Watering Down”: Drug Transparency Bill Stripped of Critical Provisions Ahead of Senate Vote

ProPublica · Naisha Roy